GLP3 20mg · Retatrutide · ≥99% Purity · Triple Receptor Agonist · Elixser Peptides

Compound Profile

Researcher-grade specs. No guesswork.

Each vial ships with the structural data and lot identifiers researchers need for traceable, reproducible work.

Built for the bench.

Synthesized via solid-phase peptide chemistry with site-specific lipidation, purified by reverse-phase HPLC, verified by mass spectrometry, and tested for sterility and endotoxin load. Every spec below is documented on the signed Certificate of Analysis that ships with your vial.

View signed COA

Compound

Retatrutide

Synonyms

GLP3, LY3437943, Triple G

Class

Triple receptor agonist

Targets

GLP-1, GIP, glucagon receptors

CAS Number

2381089-83-2

Molecular Formula

C₂₂₃H₃₄₃F₃N₄₆O₇₀

Molecular Weight

4845.44 g/mol

Concentration

20 mg / vial

Form

White powder

Purity (HPLC)

≥ 99%

Storage

2-8°C, sealed, dry

Origin

Made in the USA

In the Literature

What researchers are studying.

A short, sourced summary of where Retatrutide appears in the published research record. For context only. Not a claim, not a protocol, not advice.

Retatrutide (also known as LY3437943, GLP3, or Triple G) is a synthetic lipidated peptide developed by Eli Lilly that simultaneously activates three incretin and metabolic receptors: GLP-1, GIP, and glucagon. It is the first triple receptor agonist of its kind to reach late-stage clinical investigation.

Published research is concentrated in Phase 1, 2, and 2a randomized clinical trials across obesity (Jastreboff et al., NEJM 2023), type 2 diabetes (Rosenstock et al., Lancet 2023), and metabolic dysfunction-associated steatotic liver disease (Sanyal et al., Nat Med 2024). Multiple meta-analyses have followed since 2024.

Retatrutide is currently in Phase 3 clinical trials (the TRIUMPH program) under sponsorship by Eli Lilly. It has not been approved by the FDA for any therapeutic indication and remains classified as an investigational compound for research purposes.

For research use only. Statements above describe published research literature and do not constitute health, medical, or therapeutic claims. Not for human or veterinary use. Not evaluated by the FDA. Not Eli Lilly product. This is a research-grade synthesized peptide for in vitro analytical work.

Documented Research Areas

Triple receptor agonism: GLP-1 + GIP + glucagon
Body weight and adiposity (Phase 2 obesity trials)
Glycemic control in type 2 diabetes (Phase 2)
Hepatic fat and MASH/NAFLD (Phase 2a)
Lean mass and fat mass research (clinical trial endpoints)
Lipid profile and metabolic markers
Pulsatile incretin signaling pharmacology

Selected Studies · Peer-Reviewed Literature

A curated list of published peer-reviewed clinical trial reports, mechanism-of-action papers, and meta-analyses indexed in PubMed where Retatrutide has been studied. Provided for research-context only. Linking to the literature does not constitute endorsement of any therapeutic application.

Jastreboff AM, et al. (2023) · N Engl J Med · LANDMARK Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial PubMed · 37366315
Rosenstock J, et al. (2023) · Lancet · Phase 2 T2D Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial PubMed · 37385280
Sanyal AJ, et al. (2024) · Nat Med · Phase 2a MASH Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial PubMed · 38858523
Pasqualotto E, et al. (2024) · Metabol Open · Meta-analysis Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials PubMed · 39318607
Coskun T, et al. (2025) · Lancet Diabetes Endocrinol · Body composition Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial PubMed · 40609566
Katsi V, et al. (2025) · Biomolecules · Review Retatrutide: a game changer in obesity pharmacotherapy PubMed · 40563436
Abdul-Rahman T, et al. (2024) · Eur J Pharmacol · Review The power of three: retatrutide's role in modern obesity and diabetes therapy PubMed · 39515565
Abdrabou Abouelmagd A, et al. (2025) · Proc Bayl Univ Med Cent · Meta-analysis Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials PubMed · 40291085
Sinha B, et al. (2025) · Obesity (Silver Spring) · Bayesian NMA Efficacy and safety of GLP-1 receptor agonists, dual agonists, and retatrutide for weight loss in adults with overweight or obesity: a Bayesian network meta-analysis PubMed · 40685589
Giblin K, et al. (2026) · Diabetes Obes Metab · Phase 3 program Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: rationale and design of the TRIUMPH registrational clinical trials PubMed · 41090431

Transparency

Every lot. Every researcher. Same proof.

Each batch ships with a third-party Certificate of Analysis from BioRegen Analytical. HPLC purity, mass-spectrometry identity, sterility, and LAL endotoxin screening. Every test, every lot.

Your lot number ships on the label and on the COA. Enter it in the verifier any time to retrieve the original lab report.

Verify Your Batch Download Sample COA

Certificate of Analysis

BioRegen Analytical · Independent Lab · Lot #31204

CompoundRetatrutide (LY3437943)

CAS#2381089-83-2

FormulaC₂₂₃H₃₄₃F₃N₄₆O₇₀

Mol. Weight4845.44 g/mol

Identity (LC-MS)PASS · 4845.44 Da

Purity (HPLC)99.34%

Retention Time5.42 min

Sterility / LALPASS

Date Tested2026-04-28

Sample · Live data on verifier

Pairs With

Related compounds.

Other research peptides in the Elixser catalog cited alongside GLP3 (Retatrutide) in the published research literature.

Adjacent

MOTS-c

10mg · mitochondrial-derived

Mitochondrial-derived peptide cited in metabolic and AMPK signaling research.

GHRH analog plus selective GH secretagogue, two complementary points on the somatotrophic axis.

44-AA GHRH analog with DPP-IV-resistant N-terminal modification.

$75

View →

Common Questions

Answered straight.

GLP3 is the industry shorthand for Retatrutide in the research peptide market. The compound is also commonly referenced as LY3437943 (Eli Lilly's developmental code), Triple G, or GGG Peptide. We use "GLP3" on the label because it's the most-searched naming convention among researchers comparing this triple agonist to single-agonist GLP-1 (Semaglutide) and dual-agonist GLP-1/GIP (Tirzepatide) compounds. The underlying compound on the COA and in all references is the same: Retatrutide / LY3437943.

No. Retatrutide is currently in Phase 3 clinical trials (the TRIUMPH program) under sponsorship by Eli Lilly. It has not been approved by the FDA for any therapeutic indication. This product is sold strictly as a research-grade synthesized peptide for in vitro analytical work, not as a therapeutic. It is not the Eli Lilly clinical formulation.

Every lot is tested by reverse-phase HPLC and certified at ≥99% purity. The Certificate of Analysis lists the exact lot purity (most lots run between 99.2% and 99.7%). Your COA ships with the vial and is also retrievable by lot number through our online verifier.

Testing is done by BioRegen Analytical, an independent third-party lab. Every batch goes through HPLC purity, LC-MS identity confirmation, sterility screening, and LAL endotoxin testing. The signed Certificate of Analysis ships with each vial. Same lot number, same COA, every time.

Made in the USA. Synthesized in a US cGMP-aligned facility. Tested by a US-based independent lab. Shipped from US fulfillment.

Orders ship via 2-day expedited delivery from US fulfillment. Free over $150. Vials are sealed, packaged with insulation, and shipped in tamper-evident packaging. Tracking number is sent the same day your order leaves the warehouse.

30-day money-back guarantee on every order. If a vial arrives damaged, fails to match the COA, or you change your mind within 30 days, contact us and we will refund or replace. No restocking fees, no return shipping cost on defective product.

One sealed 20mg vial of Retatrutide (GLP3) as a white powder. Lot-stamped label with compound identifier. Signed Certificate of Analysis. Tamper-evident packaging. Bacteriostatic water for reconstitution research is sold separately and can be added in the cart.

Store sealed at 2-8°C, away from direct light, heat, and moisture. Sealed shelf life is 24 months from the date on the COA. Once reconstituted for research, store reconstituted material refrigerated and follow standard peptide-handling protocols for your lab.

No. All Elixser Peptides products are sold strictly for laboratory research and in vitro study. They are not drugs, food, or cosmetics. They are not for human or veterinary use, consumption, or therapeutic application. They have not been evaluated by the FDA. By purchasing, you agree to use these materials in compliance with applicable laws and ethical research standards.

Research Use Only

GLP3

Researcher-grade specs. No guesswork.

Built for the bench.

What researchers are studying.

Every lot. Every researcher. Same proof.

Related compounds.

Answered straight.

Add GLP3 20mg to your research arsenal.